Health insurance company Alignment Healthcare (NASDAQ: ALHC) beat Wall Street’s revenue expectations in Q3 2026, with sales up 36.7% year on year to $1.36 billion. Revenue guidance for the full year exceeded analysts’ estimates, but next quarter’s guidance of $1.32 billion was less impressive, coming in 1.3% below expectations. Its non-GAAP profit of $0.05 per share was in line with analysts’ consensus estimates.

Is now the time to buy ALHC? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

Alignment Healthcare’s third quarter was marked by strong top-line growth, but the market responded negatively as cost pressures and operational challenges surfaced. Management attributed these headwinds primarily to volatility from the migration to a new claims system, which led to a spike in provider appeals and disputes, as well as higher catastrophic and skilled nursing costs. CEO John Kao described the cost trends as “notable,” adding, “We experienced greater volatility in claims processing” following the system migration. The company responded with enhanced payment integrity controls and targeted clinical resource deployment.

Looking ahead, Alignment Healthcare’s guidance reflects a prudent approach as the company expects elevated medical cost trends to persist into the next quarter. Management emphasized that ongoing investments in clinical programs and claims processes are intended to stabilize costs and restore margins, but these benefits are not yet factored into near-term forecasts. CFO Jim Head cautioned that guidance assumes “a continuation of the elevated medical claims expense we experienced in Q3, with no contemplation of the stabilizing trends we observed in both September and October.” The company plans to focus on execution and operational consistency to position itself for improved performance in 2027.

Key insights from management’s remarks

Management cited the claims system migration, provider cost disputes, and a setback in Stars ratings as major drivers of Q3 performance and cautious guidance.

• Claims system migration impact: The move to the Facets claims adjudication platform caused temporary volatility, resulting in a spike in claims appeals and disputes. Management noted this created higher short-term costs but expects the new system to drive faster payments and better integrity controls over time.
• Provider cost pressures: CEO John Kao highlighted increased costs from catastrophic cases and skilled nursing as additional drivers of elevated medical expenses. These specific categories pressured medical loss ratios and required targeted mitigation efforts.
• Stars rating setback in California: The company’s key California HMO contract fell to a 3.5 Star Rating, below internal expectations. Management tied this shortfall primarily to triple-weighted measures, especially in Health Outcomes Survey (HOS) and Part D performance, prompting renewed focus on provider and member engagement initiatives.
• Operational responses and investments: In response to cost and quality challenges, Alignment Healthcare ramped up investment in payment integrity, implemented prepay claims edits, expanded post-pay reviews, and reallocated clinical resources for more consistent best practices across markets.
• Network and product adjustments: The company reevaluated its bid and growth strategies for 2027, making changes to networks and product emphasis in specific markets to better balance growth and margin goals. Management indicated ongoing efforts to diversify membership beyond the heavily weighted California HMO plan.

Drivers of future performance

Alignment Healthcare’s outlook is shaped by persistent cost headwinds, ongoing operational investments, and strategic adjustments to its network and product portfolio.

• Sustained medical cost pressure: Management expects elevated claims costs—especially from appeals, catastrophic care, and skilled nursing—to persist through the next quarter. Guidance assumes no immediate benefit from recent operational initiatives, reflecting a cautious stance.
• Operational and clinical investments: The company is investing in payment integrity, clinical program scale-up, and member engagement, which are expected to stabilize costs and improve metrics like Stars ratings over time. However, management stated these benefits will be gradual and are not embedded in near-term forecasts.
• Strategic network and product shifts: Alignment Healthcare is adjusting its market-level growth plans and network partnerships. This includes slower California growth, targeted expansion in other states, and a more balanced product mix to mitigate risk and support long-term profitability.

Catalysts in upcoming quarters

In coming quarters, our analyst team will be watching (1) signs that medical cost trends are stabilizing following the claims system migration and payment integrity enhancements, (2) progress toward regaining higher Stars ratings, especially for the California HMO contract, and (3) diversification of growth through network expansion and new market entries. Execution on operational improvements and member engagement initiatives will be critical milestones for Alignment Healthcare’s return to margin expansion.

Alignment Healthcare currently trades at $7.44, down from $8.03 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).

High quality stocks for all market conditions

ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.

Find out which 5 stocks it’s flagging this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.